patients underwent surgical resection for tumors involving the sternum. The series included 20 primary malignant tumors, 4 desmoid tumors, 2 malignant tumors infiltrating the sternum from adjacent organs, 19 local recurrences or metastases of breast tumors, and 7 metastases of other tumors. Total sternectomy was performed in 5 patients, subtotal sternal resection in 19, and partial resection (less than 50% of the sternum) in 28. Concurrent en bloc resection included anterior ribs in 37 patients, clavicle in 11, lung in 12 patients, pericardium in 7, and diaphragm in 2. The chest was reconstructed with prosthetic material and a myocutaneous flap in 26 patients (50%), prosthetic material only in 12 patients (23%), a myocutaneous flap in 5 patients (10%), and other techniques in the remaining patients. In 47 patients (90%) the resection was radical, and in the remaining 5 patients it was palliative. Results: No perioperative deaths occurred. After a median follow-up of 39 months, the overall 3-year survival was 58% and the S-year survival 46%, with a median survival of 50 months. In 24 patients with primary tumor the S-year survival after radical resection was 63%, and in 23 patients with secondary invasion (direct extension or metastasis) the S-year survival was 38% (median 35 months). In recurrent breast cancer the S-year survival was 48% in patients with direct extension to the chest wall and 60% in patients with distant bone metastasis. Conclusions: Our experience demonstrates that sternal resection is a safe and effective treatment, which may improve the patient's quality of life and achieve a long-term survival not only in primary tumors but also in selected secondary malignant tumors of the sternum. (J Thorac Cardiovasc Surg 1997;114:93-9) 
controversy for secondary malignant tumors of the sternum, and particularly for recurrence or metastasis of breast cancer. 7 In recurrent breast cancer, surgery has usually been performed for palliation after failure of radiation, but recently an increase in survival has been reported after resection, a' 9 On the other hand, sternal resection of metastases from other distant tumors is occasionally performed with a purely palliative intent. This article reports our experience with sternal resections for primary or secondary tumors.
Materials and methods
Between January 1980 and December 1993, at the Division of Thoracic Surgery of the Istituto Nazionale Tumori, 52 consecutive patients underwent sternal resection for tumors involving the sternum, costochondral cartilages, anterior ribs, parasternal soft tissues, or a combination of these structures (Table I) .
Primary malignant tumors comprised the main group, encompassing 20 cases (39%); in addition, there were 4 (8%) desmoid tumors, 2 (4%) tumors infiltrating the sternum from adjacent organs, 19 (37%) recurrences or metastases from breast cancer, and 7 (14%) metastases from other tumors. Twenty-one patients were male (mean age 48 years, range 16 to 75 years) and 31 were female (mean age 53 years, range 23 to 77 years).
Of the 20 primary malignant tumors (Table II) , 19 were sarcomas (the main types being chondrosarcoma in 7 and osteosarcoma in 3) and 1 was a non-Hodgkin's lymphoma of the sternum. Two patients with primary malignant tumors had radiation-induced sarcomas of the sternum occurring 13 and 14 years after high-dose mediastinal irradiation (76 and 126 Gy, respectively) for Hodgkin disease. Four patients with desmoid tumors were included in this series because their surgical management was similar to that of patients with malignant tumors; however, they were analyzed separately in the survival curves. One patient had lung cancer involving the anterior ribs and costochondral cartilages, and another had laryngeal cancer involving the upper part of manubrium.
Nineteen patients had locoregional recurrence of breast cancer: relapse was in the soft tissues of the parasternal area or at the level of the internal thoracic lymph nodes in 14 patients, and a solitary metastasis within the sternum occurred in 5 patients. Seven patients underwent surgical treatment for sternal metastases of various tumors, including 2 synovial sarcomas, 2 thyroid cancers, 2 lung cancers, and 1 gastric cancer. Thirty-nine (75%) patients had chest pain. Seventeen patients had received preoperative radiotherapy and 12 had had preoperative chemotherapy for the chest wall lesion. The diagnosis and surgical management were based on the history of the disease, clinical findings of a mass or pain (or both), and computed tomographic or magnetic resonance imaging (or both). In a few cases in which clinical and radiologic findings clearly indicated the presence of a primary malignant tumor of the sternum, we have performed radical en bloc resection without prior biopsy. Possible invasion of lung, pericardium, diaphragm, or clavicle was assessed by computed tomography or magnetic resonance imaging.
Follow-up was updated in July 1995, after a minimum observation of 18 months. The actuarial survival from the time of sternal resection was calculated with life table analysis according to the method of Kaplan and Meier, and statistical analysis was performed by the log-rank test.
Results

Resection and reconstruction.
Complete resection of the sternum was performed in 5 patients (10%), subtotal resection encompassing more than 50% of the sternum in 19 patients (37%), and partial resection including less than 50% of the sternum in 28 patients (54%) ( Table III) .
En bloc resection including the anterior segment of ribs was carried out in 37 patients (71%); more than five ribs were resected in 2 patients, three or four in 18, and one or two in 17 patients; resection was limited to the costal cartilages in the remaining patients (Table III) . The average defect created by resection of the sternum (and ribs) was 10 x 7.5 cm, and the largest defect was 27 × 12 cm. Concurrent (Table III) .
Various types of reconstruction were applied (Table IV), d e p e n d i n g on the individual surgeon's choice: Marlex mesh was the prosthetic m a t e r i a l used most often (38 patients, 73%); m y o c u t a n e o u s flaps were used in 31 patients (60%); in 26 patients prosthetic materials were used in conjunction with myocutaneous flaps (50%); and in 5 patients flaps were used alone (10%). The intent of the operation was curative in 47 patients (90%), and in 5 it was palliative because of diseased surgical margins (3 patients) or concurrent presence of distant metastases in other organs (2 patients). In such patients we decided to operate to obtain local control of the mass, reduce the thoracic pain, and improve the quality of life. All 5 patients were in good general condition and were not suitable for palliative radiotherapy for various reasons.
Postoperative course. No perioperative deaths occurred. Fourteen patients (27% _+ 6%) were affected by minimal morbidity. Local complications occurred in 8 patients (15%). In 3 patients (1 of whom had diabetes) the wound was necrotic: this necrosis was limited and healed spontaneously in 1 patient, but in the other 2 patients excision was necessary and a myocutaneous flap was used (in the first patient a major pectoralis flap and in the second one a latissimus dorsi flap, after the previous rectus abdominis flap had been removed). One patient had a superficial infection and four had a seroma treated with medical therapy. One patient had a local sepsis that necessitated removal of the silicone prosthesis and repeated local irrigation. It was not necessary, however, to remove the Marlex mesh. Systemic morbidity occurred in 8 patients and consisted of significant pyrexia necessitating treatment with antibiotics (in 1 patient, bilateral pneumonia).
On average, the chest drains were removed 9 days after the operation (range 2 to 28 days), and after 7 days in uncomplicated cases. Average postoperative hospital stay was 14 days (range 3 to 60 days); if complicated cases are excluded, the average stay was 9 days. For prolonged loss of proteins many patients required plasma or albumin (or both); 21 patients had blood transfusion, on average 3 units per patient (range 1 to 7 units). Electrolyte alterations were infrequent and never severe.
Only 12 patients received postoperative adjuvant treatment consisting of chemotherapy (5 patients) or radiotherapy (7 patients).
Survival. After a median follow-up of 39 months, the overall 3-year survival was 58% and the 5-year survival 46%, with a median value of 50 months and a death rate per person-year (DR) of 0.14. Among the patients who underwent radical operations, 27 (53%) were alive (median survival 67 months) and 24 (47%) were free of disease (DR = 0.12). None of the five patients undergoing palliative resection survived 5 years, and the median survival was only 11 months (DR = 0.57). Fig. 2 illustrates the actuarial survival after radical resection according to the type of sternal involvement. In 24 cases of primary tumor the 5-year survival was 63% (median not reached) and in 23 cases of secondary invasion (direct extension or metastasis) the 5-year survival was 38%, with a median value of 35 months (DR = 0.07 and 0.18, respectively). Fig. 3 illustrates the survival of patients with primary tumors according to the histologic diagno-sis. All 4 patients with desmoid tumors were alive and free of disease at 5 years, whereas the 5-year survival was 60% for the 11 patients with low-grade sarcoma and 30% (median 17 months) for the 9 patients with high-grade sarcoma (DR = 0.08 and 0.27, respectively).
In patients who underwent sternal resection for recurrent breast cancer (Fig. 4) , the 5-year survival was similar regardless of whether the patient had direct extension to the chest wall or distant bone metastasis (48% vs 60%; DR = 0.15 and 0.13, respectively), with a remarkably long median survival. However, none of the 5 patients with metastatic tumors other than breast cancer survived, and the median survival was only 12 months (not shown).
Regarding symptomatic benefit, none of the patients operated on for advanced breast cancer had local tumor relapse or recurrence of symptoms, namely chest pain, during the follow-up period.
Discussion
Resection of large portions of the chest wall has been a complex problem in the past on account of technical intraoperative difficulties, surgical complications, and respiratory failure caused by the chest wall instability and paradoxic respiratory movements. Present-day cooperation between thoracic and plastic surgeons allows more aggressive resections, 2 and neither the size nor the position of the chest wall defect limits surgical management, because resection and reconstruction are performed in a single operation that provides immediate chest wall stability.
Surgery is the treatment of choice for patients with primary tumors of the chest wall including the sternum.i, 10 For some authors, survival is not significantly different between primary and recurrent sarcomas. 4 For primary malignant tumors of the chest wall, a 5-year survival range of 46% 5 to 66% 11 has been reported, with a wide difference between high-grade and low-grade sarcomas. Five-year survival ranges from 16.6% for peripheral neuroepitheliomas to 89% for chondrosarcomasJ 2 Others report that 5-year survival was 14% in osteosarcomas and 80% in chondrosarcomas. 6 After a median follow-up of 31.5 months, the survival was 79% for primary tumors and 33% for metastatic tumors2; in another series, survival was 59% without any difference among primary and recurrent tumors. 4 Our series confirms that low- grade primary sarcomas have a better prognosis than high-grade tumors (60% vs 30% at 5 years; see Fig. 3 ), although because of the limited number of observations the difference does not reach statistical significance. Desmoid tumors are considered to be a benign fibromatosis or a low-grade fibrosarcoma by pathologists, but they should be resected with wide margins in normal tissue, as are primary malignant tumors, to avoid recurrence, a Sarcomas arising in the sternum after extensive mediastinal irradiation for lymphomas may be difficult to treat. In fact, the limits between the tumor and radiation-induced fibrosis may not be properly defined, and the tumor is likely to recur despite undiseased resection margins at pathologic examination. In this series, the 2 patients with sarcomas of the sternum induced by mediastinal irradiation for Hodgkin's disease had widespread mediastinal recurrence a few months after radical sternectomy and died within 2 years of the operation.
On the other hand, the role of surgery remains a subject of controversy for recurrence and metastasis of breast cancer involving the chest wall and sternum,S, 13 in which surgery may be considered for simple palliation and local control of the disease. The actuarial 5-year survival after resection for breast cancer recurrences ranges from 34% 14 to 63% 15 in the literature. A few authors have advocated a radical surgical approach for patients with solitary breast cancer recurrence or metastasis involving the chest wall and sternum, because survival may be improved. 7'9 It has been suggested that sternal metastases may remain solitary for a long time and that their evolution may be different from that of vertebral metastases, possibly because of the lack of communication with paravertebral venous plexus through which cancer cells spread to other bones, s In our opinion, surgical therapy should be considered occasionally for isolated bone metastases of breast cancer as part of a combined multimodality approach that includes radiotherapy, chemotherapy, and hormone therapy. Adjuvant chemotherapy and hormone therapy increase the disease-free survival and overall survival. 16 The prognosis of local chest wall recurrence or metastasis of breast cancer is better in the absence of internal thoracic and mediastinal lymph node metastases; if mediastinal lymph nodes are involved, the chance of progression with metastatic dissemination is much higher. 8 Surgery may still be considered in such cases, whenever adequate local control cannot be achieved by radiotherapy or chemotherapy, to palliate thoracic pain, inflammation, infections, and bleeding associated with the recurrence. In the present series, the 5-year survival was equally good in patients with direct extension to the chest wall or distant bone metastasis (48% vs 60%, see Fig. 4 ).
Regarding the margin of resection, most authors recommend that the incision be placed 2 to 4 cm from the margin of the tumor or the irradiated tissue. 7 Others 2 advocate that a minimum of 4 cm of normal tissue be removed en bloc with fullthickness resection of the involved bone (manubrium, sternal body, or whole sternum) and corresponding anterior tract of the ribs bilaterally, one uninvolved rib and the intercostal space above and below. 4 Many materials had been used in the past for reconstruction of anterior defects of the chest wall: fascia lata, 17 rib grafts, 18 large cutaneous flaps, and contralateral breast. 19 A great advance was made when the use of a latissimus dorsi flap with preservation of the vascular thoracodorsal system was introduced.3, 2o The strategy for reconstruction now has to be based on the extent of skeletal and soft tissue defect. The potential combinations of prosthetic materials and myocutaneous flaps are countless, and often more than one option can effectively deal with the individual patient's problem. The need for skeletal reconstruction depends on the size and site of resection2: reconstruction is necessary for the sternum and for the anterior and lateral tracts of the ribs, whereas posterior defects may not require reconstruction if they are fully covered by the scap-ula without any risk of inward rotation 5 or if they can be stabilized by adjacent muscles. For some authors sternal and posterior defects require less stabilization than anterior and lateral defects. 2' 21 Various options of prosthetic materials are possible. Marlex mesh, polytetrafluoroethylene patch,* and Prolene mesh (Ethicon, Inc., Somerville, N.J.) are well tolerated, easy to handle, and must be sutured under tension, which improves the stability of the chest wall. 3' 4 Polytetrafluoroethylene has the advantage of being impervious to the flow of air and fluids. 22 Neither Marlex, Vicryl (Ethicon), nor Prolene mesh has this characteristic, but in our experience a transient flow of serum or blood through the prosthesis did not create any problem. Among the various prosthetic meshes with similar physical properties, Marlex mesh remains the most widely used because of its solidity, manageability, and long-term tolerability, the virtual absence of foreign body reactions or septic complications, and the low cost. After total sternectomy or large resections involving the lateral aspect of the chest wall and more than four ribs, the Marlex mesh-methacrylate composite offers the best results in terms of fixation, protection of endothoracic organs, and lung expansion.6, 23 The mesh-methacrylate composite is manufactured at the time of the operation, when the size and shape of the prosthesis can be determined, and provides excellent functional and cosmetic results. Paradoxic movement of the chest can be prevented with this prosthesis, even with large defects. Nonetheless, in our experience, when a partial sternal resection is performed with preservation of the anterior chest wall continuity (manubrium or a part of the sternal body with adjacent ribs), it is possible to use the simple Marlex mesh fixed under tension to obtain adequate skeletal stability.
For the reconstruction of soft tissue defects, myocutaneous flaps have replaced other tissues, such as simple skin flaps or breast transposition, because of their safety and long-term reliability. This aspect is particularly critical in managing breast cancer recurrence because of the damage caused by the previous operation and radiation to the surrounding tissues. Depending on the specific circumstances, different myocutaneous flaps can be used, alone or in combination: major pectoralis muscle to repair upper anterior defects, transverse rectus or serratus muscle for anterior and lateral defects, and latissimus *Gore-Tex patch, registered trade name of W. L. Gore & Associates, Inc., Elkton, Md.
dorsi muscle for any anterior or lateral defects. The omentum has been proposed as a valid alternative to muscular flaps for its excellent blood supply 24 and good performance in potentially infected areas. Clinical results are favorable, 25 but the obvious disadvantages are the need for additional laparotomy and alternative sources of skin cover.
In conclusion, our results confirm that even extensive resection of the sternum for primary or secondary tumors followed by reconstruction with prosthetic material or a myocutaneous flap is a safe and effective treatment. Various combinations of myocutaneous flaps and prosthetic materials can be used, and the choice of technique depends on size, position of the defect, and surgeon's preference. It is clear, however, that major resections of the sternum, en bloc with pericardium, lung, or diaphragm, can be performed with no mortality, minimum morbidity, and reasonable duration of the hospital stay. In primary tumors, as demonstrated by a recent series, 6 radical resection may provide a permanent eradication of the disease and a good prospect for longterm survival. Moreover, in patients with recurrent breast cancer, sternal resection offers not only a significant and permanent palliation but also a prolonged survival.
